MX2021004036A - Anticuerpos biespecíficos dirigidos a exosomas. - Google Patents

Anticuerpos biespecíficos dirigidos a exosomas.

Info

Publication number
MX2021004036A
MX2021004036A MX2021004036A MX2021004036A MX2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A MX 2021004036 A MX2021004036 A MX 2021004036A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
exosome
targeting
associated protein
targeting bispecific
Prior art date
Application number
MX2021004036A
Other languages
English (en)
Spanish (es)
Inventor
Matthew K Robinson
Michael John Morin
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of MX2021004036A publication Critical patent/MX2021004036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021004036A 2018-10-17 2019-10-17 Anticuerpos biespecíficos dirigidos a exosomas. MX2021004036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746862P 2018-10-17 2018-10-17
PCT/US2019/056698 WO2020081786A1 (en) 2018-10-17 2019-10-17 Exosome-targeting bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2021004036A true MX2021004036A (es) 2021-08-24

Family

ID=70284767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004036A MX2021004036A (es) 2018-10-17 2019-10-17 Anticuerpos biespecíficos dirigidos a exosomas.

Country Status (12)

Country Link
US (1) US20210347895A1 (cg-RX-API-DMAC7.html)
EP (1) EP3866851A4 (cg-RX-API-DMAC7.html)
JP (2) JP7496818B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210091714A (cg-RX-API-DMAC7.html)
CN (1) CN113423425A (cg-RX-API-DMAC7.html)
AU (1) AU2019359877A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007469A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116560A1 (cg-RX-API-DMAC7.html)
IL (1) IL282355A (cg-RX-API-DMAC7.html)
MX (1) MX2021004036A (cg-RX-API-DMAC7.html)
SG (1) SG11202103812RA (cg-RX-API-DMAC7.html)
WO (1) WO2020081786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006431A2 (pt) * 2018-10-02 2021-07-27 Immunome, Inc. anticorpos direcionados a epn1
CN113754771A (zh) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 一种抗pdl1×egfr的双特异性抗体
CN114354913B (zh) * 2021-12-31 2024-07-19 厦门大学 一种外泌体pd-l1糖基化检测方法
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023225613A2 (en) * 2022-05-18 2023-11-23 Immunome, Inc. Combination anti-epn1 and anti-pd-l1 antibody therapies
EP4630966A2 (en) * 2022-12-09 2025-10-15 The Regents of the University of California Intelligent design and engineering of proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
RU2018105846A (ru) * 2015-07-29 2019-08-28 Новартис Аг Комбинация антагониста pd-1 с ингибитором egfr
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
ES3023551T3 (en) * 2016-03-25 2025-06-02 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质

Also Published As

Publication number Publication date
AU2019359877A1 (en) 2021-05-20
WO2020081786A1 (en) 2020-04-23
JP2022512734A (ja) 2022-02-07
JP2024123004A (ja) 2024-09-10
SG11202103812RA (en) 2021-05-28
CN113423425A (zh) 2021-09-21
JP7496818B2 (ja) 2024-06-07
CA3116560A1 (en) 2020-04-23
EP3866851A4 (en) 2022-11-02
KR20210091714A (ko) 2021-07-22
EP3866851A1 (en) 2021-08-25
BR112021007469A2 (pt) 2021-08-10
US20210347895A1 (en) 2021-11-11
IL282355A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
ZA201905790B (en) Anti-lag-3 antibodies and uses thereof
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EP4491234A3 (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4442278A3 (en) Humanized antibodies against c-kit
WO2019232477A3 (en) Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
PH12019500369A1 (en) Anti-tim-3 antibodies
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
MX420258B (es) Proteínas de unión a nkg2d, cd16 y nectina 4.
MY199019A (en) Pd-1 antibodies
TN2018000044A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
EP3964527A3 (en) Combination therapy for cancer
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
HK1243631A1 (zh) 用於提高过继细胞免疫疗法效力的组合物和方法
EP4588484A3 (en) Methods of treating multiple myeloma
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof